GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.
Publication
, Journal Article
Margulies, KB; Anstrom, KJ; Hernandez, AF; Redfield, MM; Shah, MR; Braunwald, E; Cappola, TP; Heart Failure Clinical Research Network,
Published in: Circ Heart Fail
July 2014
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Circ Heart Fail
DOI
EISSN
1941-3297
Publication Date
July 2014
Volume
7
Issue
4
Start / End Page
673 / 679
Location
United States
Related Subject Headings
- Ventricular Function, Left
- Treatment Outcome
- Stroke Volume
- Insulin
- Hypoglycemic Agents
- Humans
- Heart Failure
- Glucagon-Like Peptide 1
- Clinical Trials as Topic
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Margulies, K. B., Anstrom, K. J., Hernandez, A. F., Redfield, M. M., Shah, M. R., Braunwald, E., … Heart Failure Clinical Research Network, . (2014). GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail, 7(4), 673–679. https://doi.org/10.1161/CIRCHEARTFAILURE.114.000346
Margulies, Kenneth B., Kevin J. Anstrom, Adrian F. Hernandez, Margaret M. Redfield, Monica R. Shah, Eugene Braunwald, Thomas P. Cappola, and Thomas P. Heart Failure Clinical Research Network. “GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.” Circ Heart Fail 7, no. 4 (July 2014): 673–79. https://doi.org/10.1161/CIRCHEARTFAILURE.114.000346.
Margulies KB, Anstrom KJ, Hernandez AF, Redfield MM, Shah MR, Braunwald E, et al. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail. 2014 Jul;7(4):673–9.
Margulies, Kenneth B., et al. “GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.” Circ Heart Fail, vol. 7, no. 4, July 2014, pp. 673–79. Pubmed, doi:10.1161/CIRCHEARTFAILURE.114.000346.
Margulies KB, Anstrom KJ, Hernandez AF, Redfield MM, Shah MR, Braunwald E, Cappola TP, Heart Failure Clinical Research Network. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail. 2014 Jul;7(4):673–679.
Published In
Circ Heart Fail
DOI
EISSN
1941-3297
Publication Date
July 2014
Volume
7
Issue
4
Start / End Page
673 / 679
Location
United States
Related Subject Headings
- Ventricular Function, Left
- Treatment Outcome
- Stroke Volume
- Insulin
- Hypoglycemic Agents
- Humans
- Heart Failure
- Glucagon-Like Peptide 1
- Clinical Trials as Topic
- Cardiovascular System & Hematology